https://www.selleckchem.com/pr....oducts/relacorilant.
Immortal time bias (IT can hinder appropriate interpretations of studies administering adjuvant therapies. Given the increase in National Cancer Data Base (NCD analyses evaluating postoperative radiation therapy (PORT) as an adjuvant therapy, we sought to practically demonstrate the effects of ITB by performing a series of simulated NCDB analyses. A simulated NCDB analysis was performed to examine how the reported benefit of PORT in stage III non-small cell lung cancer (NSCLC) may change with adjustment for ITB utilizing sequen